Page 196 - Comprehensive treatment of patients with glucocorticoid-dependent severe asthma

Appendix
Presentations
"Unsupervised and externally validated clinical 2018 0.5 cluster analysis from the U-BIOPRED paediatric
cohorts", thematic poster, ERS Paris
“Clinical Phenotypes of Asthma in Childhood 2017 0.5 and Adolescence: Clustering Analysis from the
Paediatric U-BIOPRED Cohorts”, poster discussion,
ATS Washington
“ Exhaled breath VOC by GCMS associates with 2015 0.5 night symptoms but not to asthma control in
children”, poster discussion, ERS Amsterdam
“Clinical and epidemiological predictors of 2013 0.5 physician confirmed wheeze in an unselected
cohort of infants (EUROPA-Study)”, thematic
poster, ATS
“Virus Dependent Changes In Exhaled Molecular 2012 0.5 Profile In Wheezy Infants. Prospective Data From
The EUROPA Study”, thematic poster, Longdagen
“Bijwerkingen van corticosteroiden bij astma”, 2012 0.5 Davos, Speaker
“Association between Rhinovirus C infection and 2012 0.5 respiratory symptom severity in an unselected
pediatric population”, thematic poster, ERS
“Tapering oral corticosteroids in severe asthma is 2011 0.5 associated with a decrease in fractional exhaled
nitric oxide”, oral presentation, ERS Amsterdam
“Reliability Of 'Doctor's Confirmed Wheeze' In 2011 0.5 Infants: Validation In The EUROPA Cohort.”, poster
discussion, ATS Denver
“Psychological Factors Contributing To Asthma 2011 0.5 Control And Asthma Related Quality Of Life In
Patients With Severe Prednisone-Dependent
Asthma”, poster discussion, ATS Denver
“Predictors of successful oral steroid tapering in 2010 0.5 severe, prednisone-dependent asthma”, thematic
poster, ERS Barcelona
194